Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment.
A double-blinded, placebo-controlled cross-over trial was carried out with 27 hypercholesterolemic men with coronary heart disease. During the 6-week treatment period lovastatin (60 mg/day) decreased fasting serum LDL cholesterol by 45%, LDL phosphorus by 38% and apoB by 33%. Ubiquinol content diminished by 13% as measured per LDL phosphorus. When LDL was oxidized ex vivo with AMVN both LDL ubiquinol and alpha-tocopherol were exhausted faster after lovastatin treatment compared to placebo, by 24% (P < 0.005) and 36% (P < 0.0001), respectively. Lag time in copper-induced oxidation of LDL decreased by 7% (P < 0.01). This suggests diminished antioxidant-dependent resistance of LDL to the early phase of oxidative stress.
Palomäki
A
A
Kanta-Häme Central Hospital, Hameenlinna, Finland.
Malminiemi
K
K
Metsä-Ketelä
T
T
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage*; D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003300:Copper; D003327:Coronary Disease / Q000150:complications* / Q000378:metabolism; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D014280:Triglycerides / Q000097:blood; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry; D014810:Vitamin E / Q000097:blood* / Q000737:chemistry
D000924:Anticholesteremic Agents; D000975:Antioxidants; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D014280:Triglycerides; D014451:Ubiquinone; D014810:Vitamin E; D003300:Copper; D002784:Cholesterol; D008148:Lovastatin; C003741:ubiquinol